http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102034958-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-015 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-085 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-015 |
| filingDate | 2018-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102034958-B1 |
| titleOfInvention | A pharmaceutical composition comprising Nm23 activator for anti-metastasis |
| abstract | The present invention relates to a pharmaceutical composition for inhibiting cancer metastasis, comprising an active agent compound of cancer metastasis suppressor Nm23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the compound according to the present invention is related to cancer metastasis. By enhancing the activity of Nm23, it can be usefully used as a pharmaceutical composition for inhibiting cancer metastasis by inhibiting cancer cell metastasis. |
| priorityDate | 2017-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 66.